[Skip to Navigation]
Sign In
Research Letter
July 2017

Intracranial Gadolinium Deposition Following Gadodiamide-Enhanced Magnetic Resonance Imaging in Pediatric Patients: A Case-Control Study

Author Affiliations
  • 1Department of Radiology, College of Medicine, Mayo Clinic, Rochester, Minnesota
  • 2Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, Minnesota
  • 3Department of Neurosurgery, College of Medicine, Mayo Clinic, Rochester, Minnesota
JAMA Pediatr. 2017;171(7):705-707. doi:10.1001/jamapediatrics.2017.0264

Approximately 40% of the 3 million annual pediatric magnetic resonance imaging (MRI) examinations in the United States are performed with intravenous administration of a gadolinium-based contrast agent (GBCA).1 Contrast-enhanced MRI provides critical clinical information that is often not apparent on unenhanced MRI or other imaging modalities. Notwithstanding their widespread use, studies demonstrating the unexpected accumulation of gadolinium within the neural tissues of adults following intravenous GBCA exposure have prompted ongoing investigations by the US Food and Drug Administration and European Medicines Agency regarding the safety and toxicity of these agents.2,3 Because these prior studies were limited to adults, the purpose of this study was to determine the extent of deposition in the GBCA-exposed population and whether prior observations were related to age-dependent breakdown of the blood-brain barrier through study of a cohort of pediatric patients who received gadodiamide-enhanced MRI examinations.


In this single-center retrospective case-control study approved by the Mayo Clinic institutional review board, postmortem brain tissues of pediatric patients (younger than age 18 years) who died between 2000 and 2015, received at least 4 gadodiamide-enhanced MRI examinations (Omniscan, 287 mg/mL, 0.1 mmol/kg; GE Healthcare, gadodiamide-exposed group), and who underwent autopsy following antemortem consent were compared with pediatric patients who did not receive any gadolinium-enhanced MRI examinations during their lifetime (control group). All clinical and imaging data were extracted from our medical record. Tissue samples were harvested from formalin-fixed whole-brain specimens at neuroanatomic locations (dentate nucleus, pons, globus pallidus, and thalamus) previously shown to be associated with increased levels of gadolinium deposition in adults.4 Hematoxylin-eosin–stained and neurofilament immunostained microscope slides were prepared using standard techniques. Gadolinium quantification and localization within tissue samples were carried out using inductively coupled plasma mass spectrometry and transmission electron microscopy with energy dispersive spectroscopy, respectively, as previously described.4


Three gadodiamide-exposed pediatric patients were compared with 3 GBCA-naive control pediatric patients (Table). Elemental gadolinium was detected in all 4 neuroanatomic regions among gadodiamide-exposed patients; the highest concentrations were detected in the dentate nucleus or pons. Transmission electron microscopy with energy dispersive spectroscopy revealed prominent clusters of gadolinium deposits within the endothelium and scattered smaller foci within the neural interstitium within these patients, indicating either direct or indirect transit across the blood-brain barrier (Figure A-B). No gadolinium was detected by inductively coupled plasma mass spectrometry or transmission electron microscopy in control patients. No pathologic changes were observed in dentate tissues of control or gadodiamide-exposed patients (Figure C-E). Dentate tissue from patients 1 and 2 who received the highest cumulative doses of gadodiamide had mildly to severely gliotic regions with prominent axonal spheroids (Figure F). It is unclear whether these pathologic changes are associated with prior external beam radiation therapy or with gadodiamide exposure.

Table.  Clinical Characteristics and Mass Spectrometry Results of Study Population
Clinical Characteristics and Mass Spectrometry Results of Study Population
Figure.  Tissue Localization and Cellular Response to Gadolinium Deposition
Tissue Localization and Cellular Response to Gadolinium Deposition

Cellular localization of gadolinium using transmission electron microscopy (TEM) on tissue samples stained with 0.2% lead citrate are shown for the dentate nuclei of control patient 1 (A) and gadodiamide-exposed patient 3 (B) at 10 000-fold magnification. X-ray spectra of a selected electron dense foci (black arrowheads) are shown in the inset of each respective panel on a selected electron dense foci; gadolinium peaks in the spectra are indicated by red color overlay. Light microscopy images of hematoxylin-eosin–stained dentate nuclei samples (original magnification × 100) are shown for control patient 1 (C) and gadodiamide-exposed patients 3 and 1 (D and E). F, Neurofilament-immunostained dentate nuclei samples (original magnification × 200) for gadodiamide-exposed patient 1. Arrowheads indicate axonal spheroids. C indicates carbon; ca, calcium; gd, gadolinium; ni, nickel; o; oxygen; and pb, lead.


Our findings confirm the presence of intracranial gadolinium deposits in pediatric patients with normal renal function following exposure to intravenous gadodiamide for MRI examinations. Although our data are limited by small sample size, the deposition appears to follow a dose-dependent trend with preferential accumulation in the dentate and deep gray nuclei, similar to what has been described in the adult population.4-6 Such confirmation indicates that this deposition occurs independently of patient age.

To our knowledge, there has been no observed adverse clinical symptom associated with gadolinium tissue deposition; yet, caution is warranted because free lanthanides are known to be neurotoxic and potentially mutagenic. Compared with adults, developing pediatric brains are more susceptible to the neurotoxic effects of heavy metal exposure, and it is possible that such susceptibility could also extend to the lanthanide-rare earth metals. For these reasons, ongoing research into the toxicology of GBCA exposure coupled with more judicious use of gadolinium contrast in the pediatric population is essential.

Back to top
Article Information

Corresponding Author: Jennifer S. McDonald, PhD, Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905 (mcdonald.jennifer@mayo.edu).

Accepted for Publication: January 30, 2017.

Published Online: May 22, 2017. doi:10.1001/jamapediatrics.2017.0264

Author Contributions: Dr J. McDonald had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: J. McDonald, R. McDonald, Jentoft, Kallmes, Eckel.

Acquisition, analysis, or interpretation of data: J. McDonald, R. McDonald, Jentoft, Paolini, Murray.

Drafting of the manuscript: J. McDonald, R. McDonald, Eckel.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: J. McDonald, R. McDonald.

Administrative, technical, or material support: R. McDonald, Jentoft, Paolini, Eckel.

Supervision: Kallmes.

Conflict of Interest Disclosures: Drs J. McDonald and Kallmes report an investigator-initiated research grant with GE Healthcare independent of this study. Dr Kallmes is a member of GE Healthcare’s Cost Effectiveness Board independent of this study. Dr Jentoft is an expert consultant for Bracco Diagnostics Inc independent of this study.

Additional Contributions: We thank Amy Bluhm, BS, Trace Christensen, BS, Jon Charlesworth, BS, and Jeffery Salisbury, PhD (Mayo Clinic, Rochester, Minnesota), for their technical expertise. No compensation was received for these contributions.

IMV. MRI Benchmark Report 2015. http://www.imvinfo.com/index.aspx?sec=mri&sub=def. Accessed May 19, 2016.
European Medicines Agency. PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorizations. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Gadolinium-containing_contrast_agents/human_referral_prac_000056.jsp&mid=WC0b01ac05805c516f. Published April 7, 2017. Accessed April 18, 2017.
FDA Drug Safety Communication. FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging. https://www.fda.gov/Drugs/DrugSafety/ucm455386.htm. Published 2015. Accessed April 18, 2017.
McDonald  RJ, McDonald  JS, Kallmes  DF,  et al.  Intracranial gadolinium deposition after contrast-enhanced MR imaging.  Radiology. 2015;275(3):772-782.PubMedGoogle ScholarCrossref
Kanda  T, Fukusato  T, Matsuda  M,  et al.  Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy.  Radiology. 2015;276(1):228-232.PubMedGoogle ScholarCrossref
Murata  N, Gonzalez-Cuyar  LF, Murata  K,  et al.  Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function.  Invest Radiol. 2016;51(7):447-453.PubMedGoogle ScholarCrossref